Treatment of post-bariatric hypoglycemia with GLP-1 antagonists
View Patent ↗Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLP1RA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.
1. A method for treating hyperinsulinemic hypoglycemia in a subject, the method comprising subcutaneously administering to the subject in need thereof an isotonic solution comprising a therapeutically effective amount of exendin(9-39) and at least one of an antimicrobial preservative, a tonicity adjusting agent, or a buffer;
wherein the therapeutically effective amount is 2-100 mg of exendin(9-39); and
wherein the exendin(9-39) is administered at a concentration of 20-45 mg/ml.
2. The method of claim 1 , wherein the tonicity adjusting agent comprises mannitol.
3. The method of claim 1 , wherein the therapeutically effective amount is 5-40 mg of exendin(9-39).
4. The method of claim 1 , wherein the exendin(9-39) is administered twice per day.
5. The method of claim 1 , wherein the exendin(9-39) is administered three times per day.
6. The method of claim 1 , wherein the patient has previously had bariatric surgery.
7. The method of claim 6 , wherein the bariatric surgery is Roux-en-Y gastric bypass, vertical sleeve gastrectomy, placement of an endosleeve device, duodenal mucosal resurfacing partial bypass of the duodenum, vagal nerve blockade, or pyloroplasty.
8. The method of claim 1 , wherein the patient has previously had gastrointestinal surgery.
9. The method of claim 8 , wherein the gastrointestinal surgery is gastrectomy, Nissen Fundoplication, or esophagectomy.
10. A method for treating hyperinsulinemic hypoglycemia in a subject, the method comprising subcutaneously administering to the subject in need thereof a therapeutically effective amount of exendin(9-39),
wherein the therapeutically effective amount is 2-100 mg of exendin(9-39);
wherein the exendin(9-39) is encapsulated in an extended release capsule; and
wherein the exendin(9-39) is administered at a concentration of 20-45 mg/ml.
11. The method of claim 10 , wherein the extended release capsule comprises a microsphere.
12. The method of claim 11 , wherein the microsphere comprises a biopolymer.
13. The method of claim 10 , wherein the extended release capsule is a nano-lipocapsule.
14. The method of claim 10 , wherein the therapeutically effective amount is 5-20 mg of exendin(9-39).
15. The method of claim 10 , wherein the exendin(9-39) is administered once per day.
16. The method of claim 10 , wherein the exendin(9-39) is administered once per week.
17. The method of claim 10 , wherein the patient has previously had bariatric surgery.
18. The method of claim 17 , wherein the bariatric surgery is Roux-en-Y gastric bypass, vertical sleeve gastrectomy, placement of an endosleeve device, duodenal mucosal resurfacing partial bypass of the duodenum, vagal nerve blockade, or pyloroplasty.
19. The method of claim 10 , wherein the patient has previously had gastrointestinal surgery.
20. The method of claim 19 , wherein the gastrointestinal surgery is gastrectomy, Nissen Fundoplication, or esophagectomy.
21. A method for treating hyperinsulinemic hypoglycemia in a subject, the method comprising:
solubilizing lyophilized exendin(9-39) with saline or other pharmacologically acceptable diluent to form an exendin(9-39) solution; and
subcutaneously administering to the subject in need thereof a therapeutically effective amount of the exendin(9-39) solution;
wherein the therapeutically effective amount is 2-100 mg of exendin(9-39); and
wherein the exendin(9-39) is administered at a concentration of 20-45 mg/ml.
22. The method of claim 21 , wherein the lyophilized exendin(9-39) is provided in dual-chamber cartridge.
23. The method of claim 21 , wherein the exendin(9-39) solution is administered using a pen injector.
24. A method for treating hyperinsulinemic hypoglycemia in a subject, the method comprising:
subcutaneously administering to the subject in need thereof a therapeutically effective amount of exendin(9-39) for a first treatment period, wherein the exendin(9-39) is administered at a first dosage; and
subcutaneously administering to the subject a therapeutically effective amount of exendin(9-39) for a second treatment period after the first treatment period, wherein the exendin(9-39) is administered at a second dosage;
wherein the exendin(9-39) is administered at a concentration of 20-45 mg/ml.
25. The method of claim 24 , wherein the second dosage is greater than the first dosage.
26. The method of claim 24 , further comprising subcutaneously administering to the subject a therapeutically effective amount of exendin(9-39) for a third treatment period after the second treatment period, wherein the exendin(9-39) is administered at a third dosage.
27. The method of claim 26 , wherein the third dosage is greater than the second dosage.
28. The method of claim 24 , wherein the first dosage is from 5-10 mg of exendin(9-39).
29. The method of claim 24 , wherein the second dosage is from 10-20 mg of exendin(9-39).
30. The method of claim 26 , wherein the third dosage is from 20-30 mg of exendin(9-39).
31. A method for treating hyperinsulinemic hypoglycemia in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of exendin(9-39) once per day or twice per day,
wherein the therapeutically effective amount is 2-100 mg of exendin(9-39);
wherein the exendin(9-39) is administered at a concentration of 20-45 mg/ml; and
wherein the exendin(9-39) is administered parenterally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, intra-peritonealy, orally, nasally, or by inhalation.
32. The method of claim 31 , wherein the exendin(9-39) is administered orally, and wherein the exendin(9-39) is co-administered with at least one of a protease inhibitor or an absorption enhancer.